KR102603824B1 - Composition for anti-obesity with synergistic effect - Google Patents
Composition for anti-obesity with synergistic effect Download PDFInfo
- Publication number
- KR102603824B1 KR102603824B1 KR1020200158277A KR20200158277A KR102603824B1 KR 102603824 B1 KR102603824 B1 KR 102603824B1 KR 1020200158277 A KR1020200158277 A KR 1020200158277A KR 20200158277 A KR20200158277 A KR 20200158277A KR 102603824 B1 KR102603824 B1 KR 102603824B1
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- obesity
- weight
- goryanggang
- parts
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 24
- 230000003579 anti-obesity Effects 0.000 title claims abstract description 22
- 230000002195 synergetic effect Effects 0.000 title description 7
- 239000000284 extract Substances 0.000 claims abstract description 60
- 235000017166 Bambusa arundinacea Nutrition 0.000 claims abstract description 23
- 235000017491 Bambusa tulda Nutrition 0.000 claims abstract description 23
- 241001330002 Bambuseae Species 0.000 claims abstract description 23
- 235000015334 Phyllostachys viridis Nutrition 0.000 claims abstract description 23
- 239000011425 bamboo Substances 0.000 claims abstract description 23
- 239000004480 active ingredient Substances 0.000 claims description 8
- 235000020765 fenugreek extract Nutrition 0.000 claims description 6
- 230000000694 effects Effects 0.000 abstract description 36
- 244000250129 Trigonella foenum graecum Species 0.000 abstract description 18
- 235000001484 Trigonella foenum graecum Nutrition 0.000 abstract description 18
- 235000001019 trigonella foenum-graecum Nutrition 0.000 abstract description 18
- 210000001789 adipocyte Anatomy 0.000 abstract description 10
- 230000002401 inhibitory effect Effects 0.000 abstract description 8
- 239000008280 blood Substances 0.000 abstract description 7
- 210000004369 blood Anatomy 0.000 abstract description 7
- 230000004069 differentiation Effects 0.000 abstract description 5
- 150000002632 lipids Chemical class 0.000 abstract description 5
- 238000002474 experimental method Methods 0.000 description 18
- 208000008589 Obesity Diseases 0.000 description 13
- 235000020824 obesity Nutrition 0.000 description 13
- 210000000229 preadipocyte Anatomy 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- ZMJBYMUCKBYSCP-UHFFFAOYSA-N Hydroxycitric acid Chemical compound OC(=O)C(O)C(O)(C(O)=O)CC(O)=O ZMJBYMUCKBYSCP-UHFFFAOYSA-N 0.000 description 10
- 239000013641 positive control Substances 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 9
- 238000000605 extraction Methods 0.000 description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 229940079593 drug Drugs 0.000 description 6
- 241000411851 herbal medicine Species 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 239000003960 organic solvent Substances 0.000 description 6
- 108010023302 HDL Cholesterol Proteins 0.000 description 5
- 206010062717 Increased upper airway secretion Diseases 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 244000018633 Prunus armeniaca Species 0.000 description 5
- 235000009827 Prunus armeniaca Nutrition 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 208000026435 phlegm Diseases 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 4
- 244000273928 Zingiber officinale Species 0.000 description 4
- 210000000577 adipose tissue Anatomy 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 230000009036 growth inhibition Effects 0.000 description 4
- 239000012046 mixed solvent Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 206010011224 Cough Diseases 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 206010037660 Pyrexia Diseases 0.000 description 3
- 235000006886 Zingiber officinale Nutrition 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 235000021588 free fatty acids Nutrition 0.000 description 3
- 235000008397 ginger Nutrition 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 210000000653 nervous system Anatomy 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- DBGIVFWFUFKIQN-UHFFFAOYSA-N (+-)-Fenfluramine Chemical compound CCNC(C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-UHFFFAOYSA-N 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 2
- LYISDADPVOHJBJ-UHFFFAOYSA-N 3-methylgalangin Chemical compound O1C2=CC(O)=CC(O)=C2C(=O)C(OC)=C1C1=CC=CC=C1 LYISDADPVOHJBJ-UHFFFAOYSA-N 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 206010008469 Chest discomfort Diseases 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- RRAFCDWBNXTKKO-UHFFFAOYSA-N eugenol Chemical compound COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 229960001582 fenfluramine Drugs 0.000 description 2
- 239000005417 food ingredient Substances 0.000 description 2
- 235000013376 functional food Nutrition 0.000 description 2
- VCCRNZQBSJXYJD-UHFFFAOYSA-N galangin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=CC=C1 VCCRNZQBSJXYJD-UHFFFAOYSA-N 0.000 description 2
- 235000009200 high fat diet Nutrition 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- SQFSKOYWJBQGKQ-UHFFFAOYSA-N kaempferide Chemical compound C1=CC(OC)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 SQFSKOYWJBQGKQ-UHFFFAOYSA-N 0.000 description 2
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 2
- IYRMWMYZSQPJKC-UHFFFAOYSA-N kaempferol Chemical compound C1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 IYRMWMYZSQPJKC-UHFFFAOYSA-N 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000002474 noradrenergic effect Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- -1 pinene Chemical compound 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- 230000004584 weight gain Effects 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- 230000037303 wrinkles Effects 0.000 description 2
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- 208000013824 Acidemia Diseases 0.000 description 1
- 208000010444 Acidosis Diseases 0.000 description 1
- 244000141218 Alpinia officinarum Species 0.000 description 1
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 1
- 241000123667 Campanula Species 0.000 description 1
- 241000703121 Campanula rotundifolia Species 0.000 description 1
- NPBVQXIMTZKSBA-UHFFFAOYSA-N Chavibetol Natural products COC1=CC=C(CC=C)C=C1O NPBVQXIMTZKSBA-UHFFFAOYSA-N 0.000 description 1
- 206010009866 Cold sweat Diseases 0.000 description 1
- 241001391944 Commicarpus scandens Species 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- UBSCDKPKWHYZNX-UHFFFAOYSA-N Demethoxycapillarisin Natural products C1=CC(O)=CC=C1OC1=CC(=O)C2=C(O)C=C(O)C=C2O1 UBSCDKPKWHYZNX-UHFFFAOYSA-N 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- WEEGYLXZBRQIMU-UHFFFAOYSA-N Eucalyptol Chemical compound C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 description 1
- 239000005770 Eugenol Substances 0.000 description 1
- 208000004248 Familial Primary Pulmonary Hypertension Diseases 0.000 description 1
- 235000004204 Foeniculum vulgare Nutrition 0.000 description 1
- 240000006927 Foeniculum vulgare Species 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- 244000062241 Kaempferia galanga Species 0.000 description 1
- 235000013421 Kaempferia galanga Nutrition 0.000 description 1
- 201000008197 Laryngitis Diseases 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 206010028735 Nasal congestion Diseases 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 102000000536 PPAR gamma Human genes 0.000 description 1
- 108010016731 PPAR gamma Proteins 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 240000007880 Phyllostachys bambusoides Species 0.000 description 1
- 235000001550 Phyllostachys bambusoides Nutrition 0.000 description 1
- 244000274050 Platycodon grandiflorum Species 0.000 description 1
- 235000006753 Platycodon grandiflorum Nutrition 0.000 description 1
- UVMRYBDEERADNV-UHFFFAOYSA-N Pseudoeugenol Natural products COC1=CC(C(C)=C)=CC=C1O UVMRYBDEERADNV-UHFFFAOYSA-N 0.000 description 1
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 244000046109 Sorghum vulgare var. nervosum Species 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 241000234299 Zingiberaceae Species 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000002429 anti-coagulating effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 239000002830 appetite depressant Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 235000004251 balanced diet Nutrition 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229930007050 cineol Natural products 0.000 description 1
- 229960005233 cineole Drugs 0.000 description 1
- CCRCUPLGCSFEDV-UHFFFAOYSA-N cinnamic acid methyl ester Natural products COC(=O)C=CC1=CC=CC=C1 CCRCUPLGCSFEDV-UHFFFAOYSA-N 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 235000020965 cold beverage Nutrition 0.000 description 1
- 235000021270 cold food Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000001916 dieting Nutrition 0.000 description 1
- 230000037228 dieting effect Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 230000007937 eating Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 229960002179 ephedrine Drugs 0.000 description 1
- 229960002217 eugenol Drugs 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- CIPSYTVGZURWPT-UHFFFAOYSA-N galangin Natural products OC1=C(Oc2cc(O)c(O)cc2C1=O)c3ccccc3 CIPSYTVGZURWPT-UHFFFAOYSA-N 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 206010018388 glossodynia Diseases 0.000 description 1
- 230000014101 glucose homeostasis Effects 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000009422 growth inhibiting effect Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000037219 healthy weight Effects 0.000 description 1
- 210000003709 heart valve Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 210000001624 hip Anatomy 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 238000007602 hot air drying Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000007603 infrared drying Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- PVJNLMXWZXXHSZ-UHFFFAOYSA-N izalpinin Natural products C=1C(OC)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=CC=C1 PVJNLMXWZXXHSZ-UHFFFAOYSA-N 0.000 description 1
- 235000008777 kaempferol Nutrition 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 230000004322 lipid homeostasis Effects 0.000 description 1
- 230000004132 lipogenesis Effects 0.000 description 1
- 230000004130 lipolysis Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- CCRCUPLGCSFEDV-BQYQJAHWSA-N methyl trans-cinnamate Chemical compound COC(=O)\C=C\C1=CC=CC=C1 CCRCUPLGCSFEDV-BQYQJAHWSA-N 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 229940124595 oriental medicine Drugs 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000003836 peripheral circulation Effects 0.000 description 1
- 210000002824 peroxisome Anatomy 0.000 description 1
- SUYJZKRQHBQNCA-UHFFFAOYSA-N pinobanksin Natural products O1C2=CC(O)=CC(O)=C2C(=O)C(O)C1C1=CC=CC=C1 SUYJZKRQHBQNCA-UHFFFAOYSA-N 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 208000008423 pleurisy Diseases 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 201000008312 primary pulmonary hypertension Diseases 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 238000001223 reverse osmosis Methods 0.000 description 1
- 210000004706 scrotum Anatomy 0.000 description 1
- 239000013535 sea water Substances 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 230000000862 serotonergic effect Effects 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 230000002295 serotoninergic effect Effects 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 229960004425 sibutramine Drugs 0.000 description 1
- UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 description 1
- USDOQCCMRDNVAH-UHFFFAOYSA-N sigma-cadinene Natural products C1C=C(C)CC2C(C(C)C)CC=C(C)C21 USDOQCCMRDNVAH-UHFFFAOYSA-N 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 230000007103 stamina Effects 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 230000035924 thermogenesis Effects 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 206010044008 tonsillitis Diseases 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 210000001631 vena cava inferior Anatomy 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 239000001841 zingiber officinale Substances 0.000 description 1
- USDOQCCMRDNVAH-KKUMJFAQSA-N β-cadinene Chemical compound C1C=C(C)C[C@H]2[C@H](C(C)C)CC=C(C)[C@@H]21 USDOQCCMRDNVAH-KKUMJFAQSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9062—Alpinia, e.g. red ginger or galangal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/346—Platycodon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Child & Adolescent Psychology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
본 발명은 고량강 추출물과 죽엽 추출물을 포함하는 항비만 조성물에 관한 것으로, 고량강과 죽엽 추출물의 조합이 지방세포 분화의 억제, 혈중 지질의 변화 등에 우수한 효과가 있으며, 나아가, 호로파, 길경 추출물 등을 더 포함하는 항비만 조성물에 관한 것이다. The present invention relates to an anti-obesity composition containing Goryanggang extract and bamboo leaf extract. The combination of Goryanggang and bamboo leaf extract has excellent effects on inhibiting adipocyte differentiation and changes in blood lipids, and furthermore includes extracts of fenugreek, Gilge, etc. It relates to an anti-obesity composition further comprising.
Description
본 발명은 고량강 추출물과 죽엽 추출물을 포함하는 항비만 조성물에 관한 것으로, 고량강과 죽엽 추출물의 조합이 지방세포 분화의 억제, 혈중 지질의 변화 등에 우수한 효과가 있으며, 나아가, 호로파, 길경 추출물 등을 더 포함하는 항비만 조성물에 관한 것이다. The present invention relates to an anti-obesity composition containing Goryanggang extract and bamboo leaf extract. The combination of Goryanggang and bamboo leaf extract has excellent effects on inhibiting adipocyte differentiation and changes in blood lipids, and furthermore includes extracts of fenugreek, Gilge, etc. It relates to an anti-obesity composition further comprising.
비만은 체내에 지방조직이 과다하게 축적된 상태로, 비만인 경우 일반적으로 체중이 많이 나가지만, 비만이 아니더라도 근육이 많은 사람도 체중이 많이 나갈 수 있기 때문에 체내에 지방조직이 과다한 상태를 비만으로 정의한다. 오랜 기간에 걸쳐 에너지 소비량에 비해 영양소를 과다 섭취할 경우 에너지 불균형에 의해 비만이 유도되며, 이 외에도 호르몬의 변화, 유전, 정신 건강 문제 및 사회경제적 요인 등이 복합적으로 관련되어 있다. 전세계적으로 비만 인구가 증가하는 추세로, 최근 성인병을 유발하는 중요한 요인으로 지목받으며 비만의 심각성이 중요한 문제로 대두되고 있다.Obesity is a condition in which excessive fat tissue is accumulated in the body. People who are obese generally weigh a lot, but even people with a lot of muscle can gain a lot of weight even if they are not obese, so obesity is defined as a condition in which there is excess fat tissue in the body. do. If nutrients are consumed excessively compared to energy consumption over a long period of time, obesity is induced due to energy imbalance, and in addition, hormonal changes, genetics, mental health problems, and socioeconomic factors are complexly related. The number of obese people is increasing worldwide, and the severity of obesity has recently emerged as an important issue as it has been pointed out as an important factor causing adult diseases.
한편, 당뇨병중 제2 형 당뇨는 비만과 많은 연관성을 나타내고 있다. 전사 인자중 하나인 PPAR (peroxisome proliferation activated receptor)는 지질과 포도당의 항상성에 관련된 효소의 유전자 발현을 조절하고, 지방 조직 생산을 촉진하는 것으로 알려져 있다. 또한, 이러한 PPAR의 기증변화가 비만을 일으키는 것으로 알려져 있다. 또한, PPARγ는 지방세포에서 발현되어 지방전구세포를 지방세포로 바꾸는 주요한 전사인자로, 이러한 기전에 의해 비만을 유도하는 것으로 알려져 있다. Meanwhile, type 2 diabetes is closely related to obesity. PPAR (peroxisome proliferation activated receptor), one of the transcription factors, is known to regulate gene expression of enzymes related to lipid and glucose homeostasis and promote fat tissue production. Additionally, it is known that these changes in PPAR cause obesity. In addition, PPARγ is a major transcription factor that is expressed in adipocytes and changes preadipocytes into adipocytes, and is known to induce obesity through this mechanism.
비만을 예방 및 개선하고, 건강 체중을 유지하기 위해서는 균형잡힌 식사와 규칙적인 운동을 통하여 평생 동안 꾸준한 관리가 필요하다. 특히 지방세포는 한번 만들어지면 크기는 줄일 수 있으나, 자연적으로 제거하는 것은 불가능하여 영구적으로 인체에 남아있게 되므로 처음부터 비만이 되지 않도록 예방하는 것이 중요하다. 비만의 예방, 개선 또는 치료를 위해서 섭취하는 칼로리를 줄이고, 활동 및 운동량을 증가시키는 방법 및 지방 흡수를 감소시키는 등의 약물을 복용하는 방법 등이 이용되고 있다.In order to prevent and improve obesity and maintain a healthy weight, consistent management throughout life is necessary through a balanced diet and regular exercise. In particular, once fat cells are created, their size can be reduced, but it is impossible to remove them naturally and they remain in the body permanently, so it is important to prevent them from becoming obese from the beginning. To prevent, improve, or treat obesity, methods such as reducing calories consumed, increasing activity and amount of exercise, and taking drugs that reduce fat absorption are used.
현재 비만을 치료하는 치료제로는 세로토닌 신경계를 저해하는 펜플루라민, 노르아드레날린 신경계를 통한 에페드린 및 카페인, 세로토닌 및 노르아드레날린 신경계에 동시에 작용하는 시부트라민 및 췌장에서 생성되는 리파아제를 저해하여 지방의 흡수를 줄여주는 오르리스타트 등의 약물이 있다. 그러나 기존에 사용되어온 약물 중 펜플루라민 등은 원발성 폐고혈압이나 심장 판막 병변과 같은 부작용을 일으켜 사용이 금지되었으며, 다른 약물들도 혈압감소나 유산혈증 등의 문제점이 발생하여 심부전, 신질환 등의 환자에는 사용하지 못하는 문제점이 있다.Current treatments for obesity include fenfluramine, which inhibits the serotonergic nervous system, ephedrine and caffeine, which act on the noradrenergic nervous system, sibutramine, which acts simultaneously on the serotonin and noradrenergic nervous system, and Orly, which reduces fat absorption by inhibiting lipase produced in the pancreas. There are medications such as Start. However, among the previously used drugs, fenfluramine has been banned due to side effects such as primary pulmonary hypertension and heart valve lesions, and other drugs have also caused problems such as decreased blood pressure and lactic acidemia, so they are not used in patients with heart failure or renal disease. There is a problem that cannot be done.
다이어트를 위한 약물의 경우, 지방축적을 억제하거나(식욕억제제, 지방생성억제제 등), 지방의 활성을 높이는(열생성, 지방분해 등) 2가지 기작으로 구분된다. 진료 후 처방받아 복용할 수 있지만 소화장애, 불면 등 부작용이 발생되어 이를 대체 할 수 있는 천연원료 개발의 필요성이 증가하고 있다.In the case of drugs for dieting, they are divided into two mechanisms: suppressing fat accumulation (appetite suppressants, lipogenesis inhibitors, etc.) or increasing fat activity (thermogenesis, lipolysis, etc.). Although it can be prescribed and taken after treatment, side effects such as digestive problems and insomnia occur, so the need to develop natural raw materials that can replace them is increasing.
본 발명의 고량강과 죽엽의 조합이 비만을 억제할 수 있는 유효한 성분임을 확인하고, 이에 더하여 그 효능을 증대하기 위한 실험을 진행하여 항비만에 탁월한 조합을 개발하게 되었다. It was confirmed that the combination of Goryangkang and bamboo leaves of the present invention is an effective ingredient that can suppress obesity, and further experiments were conducted to increase its efficacy to develop a combination excellent for anti-obesity.
본 발명은 매우 효과적인 항비만 조성물을 제공하고자 한다. The present invention seeks to provide a highly effective anti-obesity composition.
본 발명은 고량강 추출물과 죽엽 추출물을 유효성분으로 함유하는 항비만 조성물이다. 상기 추출물의 비율은, 고량강 추출물 100 중량부에 대하여, 죽엽 추출물 50 내지 150 중량부의 비율일 수 있다. 바람직하게는 죽엽 추출물 100 중량부로 같은 비율로 사용하는 것이 좋다. The present invention is an anti-obesity composition containing Goryanggang extract and bamboo leaf extract as active ingredients. The ratio of the extract may be 50 to 150 parts by weight of the bamboo leaf extract, based on 100 parts by weight of the Goryang River extract. Preferably, it is better to use the same ratio as 100 parts by weight of the bamboo leaf extract.
또한 본 발명은 호로파 추출물 및 길경 추출물을 더 포함하여 항비만 효율을 상승시키는 것이 가능하다. 상기 호로파 추출물 내지 길경 추출물은 고량강 추출물 100 중량부에 대하여, 25 내지 75 중량부인 것이 적당한데, 보다 바람직하게는 50 중량부 정도를 사용하는 것이 좋다. In addition, the present invention can increase anti-obesity efficiency by further including fenugreek extract and Gilge extract. The amount of the fenugreek extract or Gilge extract is preferably 25 to 75 parts by weight, and more preferably about 50 parts by weight, based on 100 parts by weight of the Goryangkang extract.
그리고, 상기 조성물에서 고량강 추출물 기준으로 3 내지 9 mg/kg 복용량으로 투여되는 것이 보다 효과적이다. In addition, it is more effective to administer the composition at a dose of 3 to 9 mg/kg based on the Koryanggang extract.
본 발명의 항비만 조성물은 조성물간의 상승작용을 통해 항비만 기능을 극대화할 수 있다. The anti-obesity composition of the present invention can maximize the anti-obesity function through synergistic effects between compositions.
도 1은 지방전구세포 성장 억제 실험 결과를 보여주는 그래프이다.
도 2는 분화지방세포 성장 억제 실험 결과를 보여주는 그래프이다.
도 3은 본 발명의 실시예의 투여 동물 실험결과 체중의 변화를 보여주는 그래프이다. Figure 1 is a graph showing the results of an experiment on preadipocyte growth inhibition.
Figure 2 is a graph showing the results of an experiment for inhibiting the growth of differentiated adipocytes.
Figure 3 is a graph showing changes in body weight as a result of experiments on animals administered in an example of the present invention.
본 발명에서 사용되는 고량강(Alpinia officinarum Hance)은 생강과에 속한 높이 약 1미터 되는 다년생 초본으로 뿌리줄기를 가을에 캐어 건조한 것을 사용한다. 갈랑갈, 아시아생강이라고 하며 통상적인 생강(Zingiber officinale Roscoe)과는 다소 차이가 있다. 통상의 생강(건강)은 고량강 만큼의 효과를 보여주지 못한다. 동의치료에서는 복통, 구토, 설사에 효력이 뛰어나고, 찬 음식이나 음료, 과일을 먹고 일어난 복통, 설사에도 치료 반응이 높고, 신장 기능 허약과 냉증으로 인한 정력감퇴, 설사, 이질에 효력이 있다고 전해진다. 정유의 주요성분으로는 시네올, 메칠신나메이트, 유게놀, 피넨, 카디넨이 있다. 이외에 후라보노이드로는 갈란긴, 켐페리드, 카엠프페롤, 쿼세틴, 이소람네틴, 갈란진-3-메칠 에테르 등을 함유하고 신미성분으로는 갈란골 등이 함유되어 있다. 주요 약리 작용으로는 위액분비 촉진 작용, 진통작용, 항산소결핍 작용, 항혈전 작용, 항응혈 작용, 말초순환 개선 작용 등이 있는 것으로 알려져 있다. Alpinia officinarum Hance used in the present invention is a perennial herb belonging to the ginger family with a height of about 1 meter, and the rhizome is dug up and dried in the fall. Galangal, also known as Asian ginger, is somewhat different from common ginger ( Zingiber officinale Roscoe). Ordinary ginger (health) does not show as much effect as Goryanggang. In traditional medicine, it is said to be effective in treating abdominal pain, vomiting, and diarrhea. It is also highly effective in treating abdominal pain and diarrhea caused by eating cold food, drinks, or fruit. It is also said to be effective in treating weak kidney function, loss of stamina due to poor circulation, diarrhea, and dysentery. The main components of essential oil include cineol, methylcinnamate, eugenol, pinene, and cadinene. In addition, it contains flavonoids such as galangin, kaempferide, kaempferol, quercetin, isoramnetin, and galangin-3-methyl ether, and as a sour ingredient, galangol, etc. It is known that its main pharmacological actions include promoting gastric juice secretion, analgesic action, anti-oxidation effect, anti-thrombotic action, anti-coagulant action, and improvement of peripheral circulation.
본 발명자들은 차즈기의 항비만 효과에 대하여 연구하던 중 고량강 또한 우수한 항비만 효과가 있음을 확인하였으며, 특히 고량강과 죽엽의 조합의 경우 우수한 항비만 효과가 있음을 확인하였다. 나아가 이들과 차즈기와의 조합도 상당히 우수한 효과를 보여주었다. 본 발명자들은, 고량강과 죽엽 추출물은 지방세포 분화의 억제, 혈중 지질의 변화 등의 효과가 있음을 확인하였고, 이를 유효성분으로 포함하는 포함하는 항비만 조성물을 제시하게 된 것이다. While researching the anti-obesity effect of Chazugi, the present inventors confirmed that Goryang-gang also has an excellent anti-obesity effect. In particular, the combination of Goryang-gang and bamboo leaves has an excellent anti-obesity effect. Furthermore, the combination of these with Chazugi also showed quite excellent effects. The present inventors confirmed that Goryangkang and bamboo leaf extracts have effects such as inhibition of adipocyte differentiation and changes in blood lipids, and proposed an anti-obesity composition containing them as an active ingredient.
또한, 항비만 효과를 상승시키는 추가적 추출물의 조합을 확인하고, 이를 더 포함하는 형태의 항비만 조성물을 제공하고자 한다. 나아가, 효과적인 사용량을 확인하였다. In addition, the aim is to identify combinations of additional extracts that increase the anti-obesity effect and provide an anti-obesity composition further comprising them. Furthermore, the effective usage amount was confirmed.
고량강 추출물의 경우, 체지방 축적 억제 기능성을 인정받은 건강기능식품 원료인 가르시니아캄보지아 추출물과 유사한 정도의 지방전구세포 성장 억제 효과를 보여주었다. 본 발명에서 사용되는 죽엽의 경우, 일부 효과는 있으나 만족할 만한 정도의 효과는 보여주지 않았다. 그러나, 고량강 추출물과 죽엽 추출물이 함께 사용되는 경우, 가르시니아캄보지아 추출물보다 훨씬 효과가 좋았다. 분화지방세포 성장 억제 효과의 경우도 유사한 결과를 보여주었으며, 실제 동물 실험에서도 유사한 결과를 보여주었다. In the case of Goryanggang extract, it showed a similar effect in inhibiting the growth of preadipocytes as Garcinia Cambogia extract, a health functional food ingredient recognized for its functionality in inhibiting body fat accumulation. In the case of the bamboo leaves used in the present invention, there was some effect, but it did not show a satisfactory level of effect. However, when Goryanggang extract and bamboo leaf extract were used together, the effect was much better than Garcinia Cambogia extract. The effect of inhibiting the growth of differentiated adipocytes showed similar results, and actual animal experiments also showed similar results.
죽엽은 참대 곧 왕대(Phyllostachys bambusoides Siebold & Zucc.)의 잎을 말린 것이다. 참대는 우리 나라 중부 이남에서 자란다. 여름철에 푸른 잎을 따서 바람이 잘 통하는 그늘에서 말린다. 맛은 쓰고 성질은 차다. 심경(心經) · 폐경(肺經) · 위경(胃經) · 간경(肝經)에 작용한다. 열을 내리고 가슴이 답답한 것을 낫게 하며 가래를 삭이고 경련을 진정시킨다. 열이 나고 가슴이 답답하며 갈증이 나는 데, 위열(胃熱)로 토하는 데, 가래가 나오면서 기침이 나며 숨이 찬 데, 경간, 후두염, 설창(舌瘡) 등에 쓴다.Bamboo leaves are the dried leaves of Phyllostachys bambusoides Siebold & Zucc. Chamdae grows in the central and southern regions of our country. Pick green leaves in the summer and dry them in a well-ventilated shade. The taste is bitter and the nature is cold. It acts on the heart meridian, menopause, stomach meridian, and liver meridian. It reduces fever, relieves chest tightness, removes phlegm, and soothes spasms. It is used for fever, chest tightness, thirst, vomiting due to stomach fever, coughing with phlegm, shortness of breath, liver, laryngitis, and tongue sores.
고량강 추출물 100 중량부를 기준으로 죽엽은 50 내지 150 중량부의 범위내에서 사용될 수 있는데, 너무 적게 사용하면 상승효율이 좋지 않으며, 너무 많이 필요이상으로 사용하는 경우 비례적으로 효과가 높아지지 않는다. 바람직한 사용량은 100중량부로 유사한 비중으로 사용하는 것이 효과적이었다. Based on 100 parts by weight of Goryang River extract, bamboo leaves can be used within the range of 50 to 150 parts by weight. If too little is used, the synergistic efficiency is not good, and if too much is used more than necessary, the effect does not increase proportionally. The preferred amount of use is 100 parts by weight, and it was effective to use it at a similar specific gravity.
한편, 본 발명자들은 한의학적 관점에서 호로파와 길경을 주목하였고, 이를 선택하여 실험을 해 보았다. 호로파와 길경은 그 자체적으로 항비만 효과가 효과적이지는 않았으나, 호로파와 길경을 함께 사용한 경우 나름의 의미있는 효과를 보여주었다. 호로파와 길경의 경우, 보조 상승작용을 하는 재료로서, 고량강 추출물의 절반 정도의 사용이 적절하다. 호로파와 길경은 고량강 추출물 100 중량부를 기준으로 25 내지 75 중량부가 사용될 수 있으며, 보다 바람직하게는 50중량부 정도이다. 너무 적게 사용하는 경우 보조 상승효과가 크지 않고 필요이상으로 사용하여도 비례적으로 효과가 증가하지는 않는다. Meanwhile, the present inventors paid attention to fenugreek and fennel root from an oriental medicine perspective, selected them, and conducted experiments. Although fenugreek and apricot root did not have an effective anti-obesity effect on their own, they showed significant effects when used together. In the case of fenugreek and Giljung, as an auxiliary synergistic ingredient, it is appropriate to use about half of the Goryanggang extract. Fenugreek and Gilgeung can be used in an amount of 25 to 75 parts by weight based on 100 parts by weight of Goryanggang extract, and more preferably about 50 parts by weight. If too little is used, the auxiliary synergistic effect is not significant, and if more than necessary is used, the effect does not increase proportionally.
호로파(胡蘆巴, Trigonellae Semen)의 학명은 큰 노랑꽃자리풀(Trigonella foenum-graecum L)으로 페누그리크(Fenugreek)라고 불리기도 한다. 원산지는 인도, 중국, 동남아, 유럽, 이집트, 수단, 미국, 레바논, 알젠틴 등으로, 호로파 씨는 대개 햇볕에 말려 약용으로 사용하는 것으로 알려져 있다. 호로파는 성질이 따뜻하고 독이 없어 아프리카·중동·인도 등지에서는 예부터 방광과 신장의 병을 치료하는 데에 이용했고 식은땀이 흐르거나 배가 찬 사람을 치료하는 데 이용하기도 한다.본초강목에서는 남자가 허리가 아프고 무릎이 시리며 음낭이 축축한 것을 치료하고 모든 虛寒證(허한증)과 저린 증상을 물리치며 소변을 자주 보는 증상을 치료하고 뱃속이 차가운 증상을 치료한다고 되어 있다. 최근에는 몸속의 혈당과 인슐린의 균형을 유지하는 데에 효과가 있다고 보고되고 있어 연구가 활발히 진행되고 있다. The scientific name of fenugreek (Trigonellae Semen) is Trigonella foenum-graecum L and is also called Fenugreek. Its place of origin is India, China, Southeast Asia, Europe, Egypt, Sudan, the United States, Lebanon, Argentina, etc. Fenugreek seeds are known to be usually dried in the sun and used for medicinal purposes. Fenugreek is warm and non-toxic, so it has been used in Africa, the Middle East, and India to treat diseases of the bladder and kidneys for a long time. It is also used to treat people with cold sweats or a full stomach. In the herbal medicine class, it is used to treat men's waists. It is said to treat aches, cold knees, and wet scrotum, eliminate all symptoms of lethargy and numbness, treat symptoms of frequent urination, and treat symptoms of a cold stomach. Recently, it has been reported to be effective in maintaining the balance of blood sugar and insulin in the body, so research is actively underway.
길경은 초롱꽃과의 도라지(Platycodon grandiflorum A. De Candolle)의 뿌리 또는 주피를 제거하여 만든 약재로서 길경이라는 이름은 뿌리가 단단하고 곧기 때문에 붙여진 것이다. 이 약은 냄새가 약간 있고 맛은 쓰고 매우며 성질은 어느 한쪽으로 치우치지 않고 평하다. 길경은 폐에 작용하여 해수와 가래가 많고 호흡이 불편한 증상을 치료하며, 폐를 맑게 하고 답답한 가슴을 풀어주며 뱃속의 찬 기운을 풀어주어 기침을 멈추고 담을 없앤다. 소변을 잘 보지 못하여 전신부종이 있고 소변양이 적을 때도 쓴다. 인후통, 감기로 인한 기침, 가래, 코막힘, 천식, 기관지염증, 흉막염, 두통, 오한, 편도선염 등에 사용한다. 약리작용으로 거담작용, 혈당강하작용, 콜레스테롤 강하작용, 개선균억제작용이 보고되었다.Gilgyeong is a medicinal herb made by removing the roots or pericarp of bellflower ( Platycodon grandiflorum A. De Candolle) of the Campanula family. The name Gilgyeong was given because the roots are hard and straight. This medicine has a slight odor and a bitter and bitter taste, but its properties are flat and not biased towards one side. Gilgyeong acts on the lungs to treat symptoms of excessive seawater and phlegm and difficulty in breathing. It clears the lungs, relieves stuffy chest, and relieves cold energy in the stomach, stopping coughing and removing phlegm. It is also used when there is edema throughout the body and the amount of urine is small due to difficulty in urinating. It is used for sore throat, cough due to cold, phlegm, nasal congestion, asthma, bronchitis, pleurisy, headache, chills, tonsillitis, etc. Expectorant, blood sugar-lowering, cholesterol-lowering, and antibacterial properties have been reported as pharmacological effects.
생김새는 불규칙하게 가늘고 긴 방추형이나 원추형이며 때때로 분지되어 있고 바깥면은 회갈색, 엷은 갈색 또는 흰색이다. 곧은 뿌리는 위쪽 끝에는 줄기를 제거한 자국이 오목하게 남아 있으며 그 부근에는 가는 가로 주름과 세로로 홈이 나 있으며 다소 구부러진 것도 있다. 윗부분을 제외한 뿌리의 대부분에는 거친 세로주름과 가로로 홈이 있고 또 피목모양의 가로줄이 있다. 질은 단단하나 꺾어지기 쉽다. 꺾은 면은 섬유성이 아니며 때때로 큰 빈틈이 있다. 다른 이름으로 길경근(桔梗根), 경초(梗草), 고경(苦梗), 고길경(苦桔梗), 리여(利如), 방도(房圖), 백약(白藥), 부호(符扈) 등이 있다. The appearance is irregularly elongated, spindle-shaped or conical, sometimes branched, and the outer surface is grey-brown, light brown or white. The tap root has a concave mark at the upper end where the stem was removed, and there are thin horizontal wrinkles and vertical grooves near it, and some are slightly curved. Most of the roots, except the upper part, have rough vertical wrinkles, horizontal grooves, and horizontal lines in the shape of a lanceolate tree. The quality is strong but easy to break. The broken surface is not fibrous and sometimes has large gaps. Other names include Gilgyeonggeun, Gyeongcho, Gogyeong, Gogilgyeong, Liyeo, Bangdo, Baekyak, and Fuho. etc.
본 발명은 핵심적 구성은 고량강과 죽엽의 조합이다. 이들의 조합은 항비만 효과에 상승작용을 한다. 한편, 호로파와 길경은 이를 함께 사용하여 추가한 경우 상당한 우수한 효과를 보여주었다. 핵심 유효성분인 고량강의 경우, 고량강 추출물 기준으로 3 내지 9 mg/kg 복용량으로 투여되는 경우 실질적 효과가 보다 우수하였다. The core composition of the present invention is a combination of kaoliang steel and bamboo leaves. Their combination has a synergistic effect on the anti-obesity effect. On the other hand, fenugreek and apricot root showed significant excellent effects when added together. In the case of Goryanggang, a key active ingredient, the actual effect was better when administered at a dose of 3 to 9 mg/kg based on Goryanggang extract.
한편, 본 발명에서 용어, "추출물(extract)"은 천연물로부터 분리된 활성성분을 의미한다. 추출물은 물, 유기용매, 또는 이의 혼합용매를 이용하는 추출과정으로 획득할 수 있으며, 추출액, 이의 건조 분말 또는 이를 이용하여 제형화된 모든 형태를 포함한다. 본 발명에서 길경 추출물 등은 물, 유기 용매, 또는 이의 혼합 용매를 사용하여 추출하여 사용할 수 있다. 바람직하게는 탄소수 1 내지 4의 저급알코올 또는 이들의 혼합용매에 가용한 추출물인 것이 바람직하며, 특히 에탄올을 사용하여 추출하는 것이 바람직하다. 추출한 액은 바로 사용하거나 또는 농축 및/또는 건조하여 사용할 수 있다. 유기용매를 사용하여 추출하는 경우, 메탄올, 에탄올, 이소프로판올, 부탄올, 에틸렌, 아세톤, 헥산, 에테르, 클로로포름, 에틸아세테이트, 부틸아세테이트, 디클로로메탄, N, N-디메틸포름아미드(DMF), 디메틸설폭사이드(DMSO), 1,3-부틸렌글리콜, 프로필렌글리콜 또는 이들의 혼합용매인 유기용매를 사용하며 생약의 유효 성분이 파괴되지 않거나 최소화된 조건에서 실온 또는 가온하여 추출할 수 있다. 추출하는 유기용매에 따라 약제의 유효성분의 추출정도와 손실정도가 차이가 날 수 있으므로, 알맞은 유기용매를 선택하여 사용하도록 한다. 추출 방법은 특별히 제한되지 않고, 예를 들어 냉침 추출, 초음파 추출, 환류 냉각 추출 등이 있다. 여과는 추출액으로부터 부유하는 고체 입자를 제거하는 과정으로, 면, 나일론 등을 이용하여 입자를 걸러내거나 한외여과, 냉동여과법, 원심분리법 등을 사용할 수 있으나 이에 제한되지 않는다. 추출액의 농축에는 감압농축, 역삼투압 농축 등의 방법이 사용될 수 있다. 농축 후 건조 단계는 동결건조, 진공건조, 열풍건조, 분무건조, 감압건조, 포말건조, 고주파건조, 적외선건조 등을 포함하나 이에 제한되지 않는다. 경우에 따라, 최종 건조된 추출물을 분쇄하는 공정을 추가할 수 있다. 또한, 상기 추출물은 추가의 분획 공정을 수행할 수 있다. Meanwhile, in the present invention, the term “extract” refers to an active ingredient isolated from a natural product. The extract can be obtained through an extraction process using water, an organic solvent, or a mixed solvent thereof, and includes the extract, its dry powder, or any form formulated using it. In the present invention, the Gilge extract, etc. can be extracted and used using water, an organic solvent, or a mixed solvent thereof. Preferably, the extract is soluble in lower alcohols having 1 to 4 carbon atoms or a mixed solvent thereof, and extraction using ethanol is particularly preferable. The extracted liquid can be used directly or after being concentrated and/or dried. When extracting using an organic solvent, methanol, ethanol, isopropanol, butanol, ethylene, acetone, hexane, ether, chloroform, ethyl acetate, butyl acetate, dichloromethane, N, N-dimethylformamide (DMF), dimethyl sulfoxide An organic solvent such as (DMSO), 1,3-butylene glycol, propylene glycol, or a mixed solvent thereof can be used, and the active ingredients of the herbal medicine can be extracted at room temperature or by heating under conditions where the active ingredients are not destroyed or minimized. The degree of extraction and loss of the active ingredient of the drug may vary depending on the organic solvent being extracted, so select and use an appropriate organic solvent. The extraction method is not particularly limited and includes, for example, cold needle extraction, ultrasonic extraction, and reflux cooling extraction. Filtration is a process of removing floating solid particles from the extract. The particles may be filtered using cotton, nylon, etc., or ultrafiltration, cryofiltration, centrifugation, etc. may be used, but are not limited thereto. Methods such as reduced pressure concentration and reverse osmosis concentration may be used to concentrate the extract. The drying step after concentration includes, but is not limited to, freeze drying, vacuum drying, hot air drying, spray drying, reduced pressure drying, foam drying, high frequency drying, and infrared drying. In some cases, a process of grinding the final dried extract may be added. Additionally, the extract can be subjected to further fractionation processes.
이하에서는 실시예 및 시험예 등을 통해 본 발명을 보다 상세히 설명한다. 그러나 이러한 실시예 등은 본 발명에 대한 이해를 돕기 위한 예시의 목적으로 사용된 것이며, 본 발명의 범주 및 범위가 이에 의해 제한되는 것은 아니다. Hereinafter, the present invention will be described in more detail through examples and test examples. However, these examples are used for illustrative purposes to aid understanding of the present invention, and the scope and scope of the present invention are not limited thereto.
<실시예 1><Example 1>
서울 약재상에서 구입한 고량강 2 kg을 음지 및 실온에서 5일간 건조하고 분쇄하였다. 상기 분쇄된 차즈기를 40% 주정(에탄올)30 ℓ에 침지시키고 50℃에서 24시간 동안 추출하였다. 이것을 여과지를 통하여 여과한 후 감압 조건에서 건조 및 농축하여 총 추출물 310 g을 수득하였다. 2 kg of Goryanggang purchased from a Seoul herbal medicine store was dried in the shade and at room temperature for 5 days and ground. The pulverized chazuki was immersed in 30 liters of 40% alcohol (ethanol) and extracted at 50°C for 24 hours. This was filtered through filter paper, dried and concentrated under reduced pressure to obtain a total of 310 g of extract.
<실시예 2><Example 2>
서울 약재상에서 구입한 죽엽 2 kg을 사용하여 실시예 1과 동일한 방법으로 추출하여, 총 추출물 290g을 수득하였다. Extraction was performed in the same manner as in Example 1 using 2 kg of bamboo leaves purchased from a Seoul herbal medicine store, and a total of 290 g of extract was obtained.
<실시예 3><Example 3>
서울 약재상에서 구입한 호로파 3 kg을 사용하여 동일한 방법으로 추출하여, 총 추출물 530g을 수득하였다. Extraction was performed in the same manner using 3 kg of fenugreek purchased from a Seoul herbal medicine store, and a total of 530 g of extract was obtained.
<실시예 4><Example 4>
서울 약재상에서 구입한 길경 3 kg을 사용하여 동일한 방법으로 추출하여, 총 추출물 510g을 수득하였다. Extraction was performed in the same manner using 3 kg of Gilgyeong purchased from a Seoul herbal medicine store, and a total of 510 g of extract was obtained.
<실시예 5><Example 5>
실시예 1의 고량강 추출물 100 중량부에 대하여 실시예 2의 죽엽 추출물 100 중량부의 비율로 조성물을 구성하였다. The composition was prepared in a ratio of 100 parts by weight of the bamboo leaf extract of Example 2 to 100 parts by weight of the Goryang River extract of Example 1.
<실시예 6><Example 6>
실시예 1의 고량강 추출물 100 중량부에 대하여 실시예 3의 호로파 추출물 50중량부의 비율로 조성물을 구성하였다. The composition was prepared at a ratio of 50 parts by weight of the fenugreek extract of Example 3 to 100 parts by weight of the Goryanggang extract of Example 1.
<실시예 7><Example 7>
실시예 1의 고량강 추출물 100 중량부에 대하여 실시예 4의 길경 추출물 50중량부의 비율로 조성물을 구성하였다. The composition was prepared at a ratio of 50 parts by weight of the Gilge extract of Example 4 to 100 parts by weight of the Koryanggang extract of Example 1.
<실시예 8> <Example 8>
실시예 5에 대하여, 고량강 추출물 100중량부를 기준으로, 실시예 3의 호로파 추출물 50 중량부의 비율로 조성물을 구성하였다. For Example 5, the composition was composed of 50 parts by weight of the fenugreek extract of Example 3 based on 100 parts by weight of the Koryanggang extract.
<실시예 9> <Example 9>
실시예 5에 대하여, 고량강 추출물 100중량부를 기준으로, 실시예 4의 길경 추출물 50 중량부의 비율로 조성물을 구성하였다. For Example 5, the composition was composed of 50 parts by weight of the Gilge extract of Example 4 based on 100 parts by weight of the Koryanggang extract.
<실시예 10> <Example 10>
실시예 5에 대하여, 고량강 추출물 100중량부를 기준으로, 실시예 3의 호로파 50 중량부와 실시예 4의 길경 추출물 50 중량부의 비율로 조성물을 구성하였다. For Example 5, based on 100 parts by weight of Goryanggang extract, the composition was composed of 50 parts by weight of fenugreek of Example 3 and 50 parts by weight of Gilge extract of Example 4.
<독성 평가><Toxicity evaluation>
실시예들이 3T3-L1 지방전구세포의 생존율에 미치는 영향을 확인하지 위해 MTT 분석을 수행하였다. 3T3-L1 지방전구 세포는 1Х105 cells/ml의 농도로 96웰 플레이트에 시딩되었다. 그 후 분화 유도를 통해 분화된 세포에 50~250ppm 농도로 실시예들과 음성대조군으로 DW를 처리 후 2일 간 배양하였다. 2일 후, 0.5mg/ml의 MTT 시약이 포함된 배지로 교체한 후 1시간 동안 배양하였다. 그 후, 배지는 버리고 생성된 포르마잔(formazan)을 녹이기 위해 DMSO 100 μl를 분주하여 540 nm의 파장에서 흡광도를 측정하였다. MTT analysis was performed to confirm the effect of the examples on the survival rate of 3T3-L1 preadipocytes. 3T3-L1 preadipocytes were seeded in 96-well plates at a concentration of 1Х10 5 cells/ml. Afterwards, cells differentiated through differentiation induction were treated with DW as examples and negative controls at a concentration of 50 to 250 ppm and cultured for 2 days. After 2 days, the medium was replaced with 0.5 mg/ml MTT reagent and cultured for 1 hour. Afterwards, the medium was discarded, 100 μl of DMSO was dispensed to dissolve the produced formazan, and the absorbance was measured at a wavelength of 540 nm.
모든 농도에서 음성대조군과 대비하여 유의한 차이를 보이지 않아, 세포독성은 문제되지 않는 것으로 판단하였다. There was no significant difference compared to the negative control group at all concentrations, so it was judged that cytotoxicity was not a problem.
<지방전구세포 성장 억제 실험><Experiment to inhibit growth of preadipocytes>
3T3-L1 지방전구세포를 96-웰 플레이트 내에서 1x104 cells/ml의 밀도로 인큐베이션시켰다. 음성 대조군(DMSO용매 대조군)을 제외하고, 가르시니아캄보지아 추출물(양성대조군) 및 실시예를 100 ppm의 농도로 세포에 처리하였다. 각 그룹에 대하여 3회 반복수행하여 평균값을 사용하였다. 가르시니아캄보지아 추출물은 체지방 축적 억제 기능성을 인정받은 건강기능식품 원료이다. 투여 과정 및 48시간 인큐베이션 후, 세포 성장 상태를 기록하였고, 3T3-L1 지방전구세포에 대한 각각의 실험 물질의 성장 억제 효과를 MTT 분석에 의해 분석하였다. 3T3-L1 preadipocytes were incubated at a density of 1x10 4 cells/ml in a 96-well plate. Except for the negative control group (DMSO solvent control group), cells were treated with Garcinia cambogia extract (positive control group) and Examples at a concentration of 100 ppm. Each group was repeated three times and the average value was used. Garcinia cambogia extract is a health functional food ingredient recognized for its functionality in inhibiting body fat accumulation. After the administration process and 48 hours of incubation, the cell growth status was recorded, and the growth inhibitory effect of each test substance on 3T3-L1 preadipocytes was analyzed by MTT analysis.
결과를 도 1에 대조군과 비교하여 나타내었다. 양성대조군인 가르시니아캄보지아 추출물보다 고량강 추출물이 더 좋은 결과를 보여주지는 않았으나, 거의 유사한 정도의 효과를 보여주었다. 죽엽, 호로파, 길경 자체적으로는 다소의 효과는 있으나, 유의미한 결과를 보여주지는 않았다. 그러나, 고량강과 죽엽의 조합인 실시에 5의 경우, 양성 대조군보다 우수한 효과를 보여주어 이들 조합의 상승 효과가 확인되었다. 그리고, 이들 조합에 호로파와 길경을 각각 단독으로 추가하는 경우에도 큰 변화를 보여주지는 않았다, 그러나, 호로파와 길경을 함께 사용하여 추가한 실시예 10의 경우 가장 우수한 결과를 보여주었다. The results are shown in Figure 1 compared to the control group. Although the Goryanggang extract did not show better results than the positive control Garcinia cambogia extract, it showed almost similar effects. Bamboo leaves, fenugreek, and apricot root themselves had some effect, but did not show significant results. However, in the case of 5, which is a combination of Goryanggang and bamboo leaves, it showed a superior effect than the positive control group, confirming the synergistic effect of these combinations. Also, adding fenugreek and apricot root alone to these combinations did not show a significant change. However, Example 10, in which fenugreek and apricot root were added together, showed the best results.
<분화 지방세포 성장 억제 실험><Experiment to inhibit growth of differentiated adipocytes>
3T3-L1 세포를 12-웰 플레이트 내에서 1x105 세포/웰의 밀도로 인큐베이션시켰다. 3T3-L1 지방전구세포는 10% BCS, 1% P/S가 포함된 배지에서 배양되었으며 배양환경은 37℃, 5%의 이산화탄소가 유지되었다. 세포의 컨플루언시(confluency)가 꽉 차고 이틀 후 (Day0), 5μg/ml insulin, 1 dexamethasone, 0.5mM IBMX, 10% FBS가 포함된 분화 유도 배지로 교체되었다. Day2부터는 5 μg/ml insulin, 10% FBS만이 포함된 배지로 교체되었으며 이틀에 한번 새 배지로 교체하며 8일간 배양하였다. Day0부터 추출물을 세포에 처리하였으며, 세포에 처리되는 최종농도는 차즈기의 농도 기준으로 250ppm이다.3T3-L1 cells were incubated at a density of 1x10 5 cells/well in 12-well plates. 3T3-L1 preadipocytes were cultured in medium containing 10% BCS and 1% P/S, and the culture environment was maintained at 37°C and 5% carbon dioxide. Two days after cell confluency was reached (Day 0), the medium was replaced with differentiation induction medium containing 5 μg/ml insulin, 1 dexamethasone, 0.5mM IBMX, and 10% FBS. From Day 2, the medium was replaced with only 5 μg/ml insulin and 10% FBS, and cultured for 8 days, replaced with new medium every two days. The extract was treated with the cells starting from Day 0, and the final concentration applied to the cells was 250 ppm based on the concentration of Chazugi.
결과를 도 2에 대조군과 비교하여 나타내었다. 양성대조군인 가르시니아캄보지아 추출물보다 고량강 추출물이 더 좋은 결과를 보여주지는 않으나 비교적 유사한 정도의 효과를 보여주어 고량강 자체도 상당한 의미가 있음을 확인하였다. 실시예 5와 같이 고량강과 죽엽을 함께 사용하는 경우, 그리고 실시예 10과 같이 고량강, 죽엽, 호로파, 길경을 함께 사용하는 경우 우수한 효과를 보여주었다. 전체적으로, 지방전구세포 성장 억제 실험의 결과와 유사 경향을 보여주었다. The results are shown in Figure 2 compared to the control group. Although the Goryanggang extract did not show better results than the positive control Garcinia Cambogia extract, it showed a relatively similar effect, confirming that the Goryanggang itself was of considerable significance. Excellent effects were shown when Goryanggang and bamboo leaves were used together as in Example 5, and when Goryanggang, bamboo leaves, fenugreek, and Gilgyeong were used together as in Example 10. Overall, it showed a similar trend to the results of the preadipocyte growth inhibition experiment.
<비만 유도 후 체중 변화실험><Weight change experiment after inducing obesity>
본 실험에서는 8주령의 암컷 B6 마우스를 사용하였다. 본 실험에는, 각각 정상 대조군, 비만 대조군, 실시예의 추출물을 투여한 그룹으로 구분하였다. 각 그룹에서는 5마리의 암컷 마우스를 사용하여 본 실험을 수행하였다. 실험 기간 동안, 정상-지방 식이를 공급한 정상 대조군의 마우스를 제외하고, 다른 그룹의 마우스에는 연속하여 8주 동안 고지방 식이를 공급하여 비만을 유도하였다. 동시에, 실험 물질을 8주 동안 매일 경구 투여하였다. 지방전구세포 성장 억제 실험과 분화지방세포 성장 억제 실험을 통해 얻은 결과를 반영하여, 가르시니아캄보지아 추출물을 양성대조군으로 하고, 실시예 1, 5, 10의 조합에 대하여 효과가 있는지를 검증하였다. 그룹 내 마우스간의 체중 및 체지방 차이를 평가하였고 각각의 동물의 체중 및 평균 식품 섭취를 실험 기간 동안 매주 기록하였다. In this experiment, 8-week-old female B6 mice were used. In this experiment, the groups were divided into normal control group, obese control group, and group administered the extract of the example. This experiment was performed using 5 female mice in each group. During the experiment, except for the normal control group of mice fed a normal-fat diet, mice in other groups were fed a high-fat diet for 8 consecutive weeks to induce obesity. At the same time, the test substances were administered orally daily for 8 weeks. Reflecting the results obtained through the preadipocyte growth inhibition experiment and the differentiated adipocyte growth inhibition experiment, Garcinia cambogia extract was used as a positive control, and the effectiveness of the combination of Examples 1, 5, and 10 was verified. Differences in body weight and body fat between mice within groups were assessed, and each animal's body weight and average food intake were recorded weekly during the experiment.
최종 체중 변화량을 도 3에 나타내었다. 정상대조군의 경우 9g 정도의 체중 증가를 보였으며, 고지방 식이를 한 비만 대조군의 경우 33.5g의 체중이 증가하였다. 양성 대조군인 가르시니아캄보지아 추출물을 투여한 경우, 14.8g의 체중 증가를 보여 항비만 효과가 있음을 보여주었다. 한편, 실시예 1의 경우 양성대조군보다는 다소 효과가 떨어지나, 그와 유사한 정도의 효과를 보였다. 실시예 5와 실시예 10의 경우, 양성대조군보다 우수한 효과를 보여주었다. 실시예 10의 경우 정상대조군에 유사한 정도의 효과를 보여주었다. The final weight change is shown in Figure 3. The normal control group showed a weight gain of approximately 9g, and the obese control group on a high-fat diet gained 33.5g. When garcinia cambogia extract, which was a positive control, was administered, a weight gain of 14.8 g was observed, showing an anti-obesity effect. Meanwhile, Example 1 was somewhat less effective than the positive control group, but showed a similar level of effect. In the case of Example 5 and Example 10, it showed a superior effect than the positive control group. Example 10 showed a similar level of effect to the normal control group.
<혈액생화학 지표의 변화><Changes in blood biochemical indicators>
상기 동물 실험 개시 전과 8주 후 16시간 이상 절식(물은 공급)시킨 다음 이소플루란(isoflurane, Baxter, USA) 흡입을 통해 1차 마취시킨 후 복부 하대정맥(inferior vena cava)으로부터 공복 혈액을 채취하여 혈장에 존재하는 총 콜레스테롤(Total-cholesterol; Total-C), 중성지방(Triglyceride;TG), 유리지방산(Free fatty acid; FFA), 고밀도지질단백질-콜레스테롤(HDL-cholesterol; HDL-C), 및 비고밀도 지질단백질-콜레스테롤(nonHDL-cholesterol; nonHDL-C)의 양을 측정하였다. 비만대조군은 정상대조군에 비해 5가지 지질의 함량이 모두 증가하였다. 양성대조군의 경우, 비만대조군에 비해 TG, Total-C 및 FFA의 함량이 다소 감소하였으나 많은 차이를 보여주지는 않았으며, HDL-C는 유사한 수준을 보여주었으며, nonHDL-C의 함량은 유의하게 감소하였다. 이에 반하여, 본 발명의 실싱예 5, 실시예 10의 경우, 전반적으로 우수한 결과를 보여주었다. Before and 8 weeks after the start of the animal experiment, the animals were fasted (water supplied) for more than 16 hours, then first anesthetized through isoflurane (Baxter, USA) inhalation, and then fasting blood was collected from the inferior vena cava of the abdomen. Total cholesterol (Total-cholesterol; Total-C), triglyceride (TG), free fatty acid (FFA), high-density lipoprotein-cholesterol (HDL-C), and And the amount of non-high-density lipoprotein-cholesterol (nonHDL-cholesterol; nonHDL-C) was measured. The content of all five lipids in the obese control group increased compared to the normal control group. In the case of the positive control group, the content of TG, Total-C, and FFA decreased slightly compared to the obese control group, but did not show much difference. HDL-C showed a similar level, and the content of non-HDL-C significantly decreased. did. In contrast, Example 5 and Example 10 of the present invention showed excellent results overall.
<관능평가><Sensory evaluation>
본 발명의 조성물은 식품조성물로 활용이 가능한 안전한 물질이어서 성인 남자 25명, 성인 여자 25명(40대 내지 50대)를 대상으로 체중 측정, 체지방 변화 주관적 느낌(피로도, 배변효과)를 평가하였다. 위약, 가르시니아캄보지아 추출물, 실시예 1과 실시예 5, 실시예 10의 조성을 대상으로 각각에 대하여 성인남자 5명, 성인여자 5명을 배당하였다. 실시예 5, 10의 것들은 양성대조군으로 사용한 가르시니아캄보지아 추출물보다 만족도가 높은 특성을 보여주었다. Since the composition of the present invention is a safe material that can be used as a food composition, 25 adult men and 25 adult women (in their 40s to 50s) were tested for body weight measurement and subjective feelings of body fat change (fatigue, bowel movement effect). Five adult men and five adult women were assigned to each of the compositions of placebo, Garcinia cambogia extract, Example 1, Example 5, and Example 10. Examples 5 and 10 showed more satisfactory characteristics than the Garcinia cambogia extract used as a positive control.
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020200158277A KR102603824B1 (en) | 2020-11-23 | 2020-11-23 | Composition for anti-obesity with synergistic effect |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020200158277A KR102603824B1 (en) | 2020-11-23 | 2020-11-23 | Composition for anti-obesity with synergistic effect |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20220071067A KR20220071067A (en) | 2022-05-31 |
KR102603824B1 true KR102603824B1 (en) | 2023-11-20 |
Family
ID=81780147
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020200158277A KR102603824B1 (en) | 2020-11-23 | 2020-11-23 | Composition for anti-obesity with synergistic effect |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR102603824B1 (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080213414A1 (en) * | 2005-12-29 | 2008-09-04 | Di Pierro Francesco | Compositions containing phaseolus vulgaris extract and alpinia officinarum extract for the prevention and treatment of obesity and type II diabetes |
KR101685876B1 (en) * | 2015-09-14 | 2016-12-13 | 경북대학교 산학협력단 | Pharmaceutical composition comprising the extract of Platycodon grandiflorum for preventing or treating of obesity |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101848250B1 (en) * | 2016-07-28 | 2018-04-12 | 안동대학교 산학협력단 | Composition for anti-inflammatory, skin whitening and anti-obesity comprising bamboo leaf extract as effective component |
-
2020
- 2020-11-23 KR KR1020200158277A patent/KR102603824B1/en active IP Right Grant
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080213414A1 (en) * | 2005-12-29 | 2008-09-04 | Di Pierro Francesco | Compositions containing phaseolus vulgaris extract and alpinia officinarum extract for the prevention and treatment of obesity and type II diabetes |
KR101685876B1 (en) * | 2015-09-14 | 2016-12-13 | 경북대학교 산학협력단 | Pharmaceutical composition comprising the extract of Platycodon grandiflorum for preventing or treating of obesity |
Also Published As
Publication number | Publication date |
---|---|
KR20220071067A (en) | 2022-05-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR20180037693A (en) | A food composition for preventing and improving lung diseases | |
WO2011026267A1 (en) | Antiphlogistic, antioncotic and analgesic chinese herbal composition,preparative method and usage thereof | |
WO2006025696A2 (en) | Composition for suppressing cyclooxygenase and/or 5-lipoxygenase | |
KR100968674B1 (en) | Herbal composition for alcoholic hangover | |
KR101813815B1 (en) | A method for manufacturing health-promoting sphere and extract using herbal materials | |
KR102603824B1 (en) | Composition for anti-obesity with synergistic effect | |
KR20220078140A (en) | Composition for preventing or improving respiratory disease | |
CN104001045A (en) | Drug for treating dog pneumonia and preparation method thereof | |
CN106860814B (en) | Health food composition for improving female frequent micturition and urinary incontinence and preparation method and application thereof | |
CN108310156A (en) | A kind of Chinese medicine composition and preparation method thereof for treating paediatrics diarrhea | |
CN102618420A (en) | Health-care liquor and manufacturing method thereof | |
KR101804061B1 (en) | Tea for tea bag using fermented Nelumbinis Semen having mental and physical rest effect | |
WO2015149393A1 (en) | Traditional chinese medicine for treating chronic gastritis and preparation method therefor | |
CN107982510A (en) | A kind of coltsfoot frondosa oral liquid for helping to give up smoking and preparation method thereof | |
KR20220071066A (en) | Composition for anti-obesity | |
CN106310068A (en) | Traditional Chinese medicine compound for relieving cough and moistening lung for children and preparation method thereof | |
CN103830713B (en) | Be used for the treatment of medicine of chicken wind-cold type cough and preparation method thereof | |
CN114533835B (en) | A Chinese medicinal composition with effects of removing pathogenic wind and dampness, and its preparation method | |
CN103829104B (en) | Feed for treating cold cough of chicken and preparation method of feed | |
CN115737755B (en) | Traditional Chinese medicine composition for dispelling effects of alcohol, preparation method and application thereof | |
WO2018124369A1 (en) | Health enhancing pill and concentrate preparation method using morus alba and platycladus orientalis | |
KR102269820B1 (en) | Pharmaceutical composition comprising the extract of cannabis sativa as an effective ingredient for preventing or treating of obesity | |
CN105709099A (en) | Nose drop for relieving nasal polyp symptom and preparation method | |
KR20210063085A (en) | Food complex composition for Anti-obesity and preparation method | |
CN104510888A (en) | Water lily panting-calming cough-relieving syrup and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant |